ArticleCancer science2020

Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer.

Shinji Takeuchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.